Journal Guide

The European Journal of Cancer (EJC) is an international multidisciplinary oncology journal, which publishes original research, reviews, and editorial comments on basic and preclinical cancer research, translational oncology, clinical oncology - including medical oncology, paediatric oncology, radiation oncology, and surgical oncology, and cancer epidemiology and prevention.The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA).Why publish your work in the EJC?Efficient peer-review: The EJC's Editors and reviewers are committed to maintaining the high standards of the journal. All manuscripts submitted to the EJC will be evaluated by the journal's Editors. Some manuscripts may be rejected outright following this evaluation, allowing the authors to submit their work elsewhere. Those manuscripts which are judged as being eligible for consideration by the Editors will be subject to peer-review. The full peer-review policy for the EJC can be found here.The EJC has an online submission and peer-review system to facilitate the submission and peer-review of submitted manuscripts. Authors are able to upload their manuscript quickly and track the status of their manuscript throughout the review process.Online Publication as an Article-in-Press: All manuscripts that are accepted for publication in the EJC are published online as Articles-in-Press within 4 - 5 weeks of acceptance. Articles-in-Press can be cited using the unique digital object identifier (DOI) which is assigned to all papers. In addition, Articles-in-Press are indexed in PubMed.The EJC's readership: The EJC is published in print and online and is available to more than 17,000 academic and clinical institutions, personal subscribers and members of the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA). In 2011 the journal had more than 83,000 articles downloaded per month from across the world.The EJC has an iPad app, making each issue of the journal available to our readers in this format. Visit http://itunes.apple.com/us/app/ejc-app/id461022524?mt=8 to find out more.eTables of Contents: Our readers can elect to receive free eTables of Contents via email, which are sent out for each issue of the journal.Abstracting and Indexing Coverage: The EJC is included in the leading abstracting and indexing services, including PubMed/MEDLINE, Current Contents/Clinical Medicine, the Science Citation Index, the Journal Citation Reports and Scopus.HINARI: The EJC is part of HINARI (Health InterNetwork Access to Research Initiative) administered by the World Health Organisation. The HINARI Programme enables developing countries to gain access to one of the world's largest collections of biomedical and health literature.Why read the EJC?High quality original research and review articles: The EJC is a multidisciplinary journal, publishing high quality original research and review articles on basic and preclinical research, translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and cancer epidemiology and prevention from across the world.Guidelines: The EJC is privileged to publish selected treatment guidelines from the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA) and other groups.Special Series: The EJC publishes special series of papers on linked topics of particular relevance and interest to the journal's readers.EJC News and EJC News Focus: Each month, the journal publishes the EJC News, discussing and commenting on current issues in cancer, together with the EJC News Focus, a series of video interviews with key opinion leaders in oncology.

EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal's websites.EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European Association for Cancer Research (EACR), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).

The European Journal of Cancer Prevention emphasizes the rapid publication of important research into fundamental aspects of cancer prevention, making it essential reading for researchers in a wide variety of fields. The scope is wide ranging, including descriptive and metabolic epidemiology, histopathology, lifestyle issues, environment, genetics, biochemistry, molecular biology, microbiology, clinical medicine, intervention trials and public education, basic laboratory studies and special group studies.Website: www.eurjcancerprev.com.

Initial review of manuscripts averages under 4 weeksArticles published online from 5 days after acceptanceUnrivalled access to 10 million healthcare professionals through ScienceDirectOver 280,000 article downloads in 2012Impact factor of 2.905 (© Thomson Reuters Journal Citation Reports 2012)Experimental Hematology publishes original research reports (regular and fast-track submissions), reviews, perspectives, letters to the editor, and abstracts of the annual meeting of ISEH - Society for Hematology and Stem Cells. We welcome manuscripts describing basic in vitro and in vivo research centered on normal and malignant hematopoiesis as well as non-malignant hematologic diseases. Submissions focused on non-hematopoietic stem cells (e.g. mesenchymal stem cells, embryonic stem cells and induced pluripotent stems) with potential relevance to hematopoiesis are also welcome, as are studies involving experimental or early phase clinical cell transplantation. Studies employing genomic and systems biology approaches to the study of normal and malignant hematopoiesis are strongly encouraged, as are those employing model organisms.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Experimental Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology with emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.Experimental Hematology & Oncology aims to publish original work, hypothesis, commentaries and timely reviews in the closely related fields of hematology and oncology.With open access, rapid turnaround time from submission to publication and online live comments from readers, Experimental Hematology & Oncology will strive to be the hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the field of hematology and oncology.

Clinical cancer genetics has now matured to a truly multidisciplinary medical discipline in which clinical and molecular geneticists work with clinical and medical oncologists as well as with psycho-social workers.Due to the multidisciplinary nature of clinical cancer genetics most papers are currently being published in a wide variety of journals on epidemiology, oncology and genetics. Familial Cancer provides a forum bringing these topics together, focusing on the interests and needs of the clinician.The journal concentrates on clinical cancer genetics. Most major areas in the field are included, such as epidemiology of familial cancer, molecular analysis and diagnosis, clinical expression, treatment and prevention, counseling and the health economics of familial cancer.

Future Oncology takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in a new era of cancer care. The journal includes news and views, literature awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Accessible ‘at-a-glance’ formats are important in an increasingly time-constrained clinical community. The article structure has been optimized to make information immediately understandable and accessible.

The GAMO is a high-quality scientific journal (published both in print and freely available online format) that informs healthcare professionals on the most relevant and updated advances on research and education, in order to offer cancer patients multidisciplinary, state of the art care.

It is the official scientific and academic diffusion publication of the Mexican Society of Oncology (SMeO). Regular numbers are published every two months, in addition to several supplements throughout the year.

Its spaces are open to the SMeO members, as well as to any member of the medical community (both national and international) interested in using this publication to communicate his/her works under the standards of universal editorial policies.

It is the jornal of choice for oncologists in matters of research and education on surgical, medical, pediatric, gynecologic, hematologic and radiation oncology, as well as on detection, diagnosis, follow-up and rehabilitation supportive disciplines, fields where different specialties involved in the management of the cancer patient do participate.
About the journal

The mission of the GAMO consists in serving its readers in:

1. representation and promotion of the oncolgy profession throughout the country and the world
2. promotion of standards of the highest quality in the practice of multidisciplinary care for the cancer patient
3. providing educational materials on cancer and support the training of investigators, using printed and electronic media
4. promotion of both clinical and translational cancer research, with special emphasis on clinical trials
5. facilitate the professional development of trainee oncologists and their transition to academical practice, fostering the interest on care for the community
6. promotion of public policies and support and guidance instruments for the cancer patient.

The Editorial Board and Committee are comprised of different experts in the field of oncology from multiple institutions, both national and international. The Editorial Board is structured based on the editorial sections that reflect the contents of the journal. Each section is directed by a section editor who supervises peer reviewing of the works by experts on the relevant area or subject. The Editorial Board Members are regular collaborators of the journal and are appointed to a 2-year period. The Editor in Chief has a 4-year period with option to a second period for the same time.
Publication guidelines

The journal is subject to international publication guidelines that indicate how a manuscript must be prepared to be able to be published, aspects on edition and publication of articles and ethical considerations that have to be followed in the communication of results.
Article types

The journal includes several types of articles. According to the structure, focus, contents, scope and purposes of the document, they can be classified as:

• Editorial
• Original articles
• Review articles
• Clinical cases

The articles can support their proposals, findings and conclusions using tables and images.

The articles are subject to peer review as a control method with regard to quality and veracity of the contents.

Submission: electronic format or by postal mail. The articles are published online in the website and sent to the SMeO members.

Gastric Cancer, a joint official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, publishes significant studies related to stomach neoplasms. The journal welcomes original articles, case reports, short communications, and technical notes, which will be peer-reviewed by the editorial board. Letters to the Editor commenting on articles published in the journal or expressing views on topics concerning gastric cancer are also welcomed. Review articles are in principle solicited by the Editor. Meeting reports will include summaries of symposia or consensus achieved in the congresses of related associations.

Genes & Cancer, peer-reviewed and published monthly, covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, articles in Genes & Cancer explore the emerging areas of genomics, drug development, and systems biology.

Genes, Chromosomes & Cancer will offer rapid publication of original full-length research articles , perspectives , reviews , letters to the editors , as well as editorial commentaries on genetic analysis as related to the study of neoplasia. Particular emphasis will be placed on work combining molecular and cytogenetic analyses of the genomic alterations of cancer cells. While preference will be given to research using analytical approaches, descriptive studies and case reports will also be welcomed, particularly when they offer insights regarding basic biologic mechanisms or the clinical management of neoplastic disorders. Specific areas covered will include:

Effective with the 2011 volume, this journal will be published in an online-only format Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

Infectious Agents and Cancer is ready to receive manuscripts on all aspects of the pathogenic mechanisms of chronic infections and progression to oncogenesis.

International Journal of Breast Cancer is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies related to all aspects of breast cancer.

Aims and Scope TheInternational Journal of Cancer(official journal of the Union for International Cancer Control - UICC) appears 24 times per year.International Journal of Cancerinvites submissions under a broad scope of topics relevant to experimental and clinical cancer research and publishes original research articles. mini reviews. short reports. and letters to the editor. The article categories within the journal are: carcinogenesis. cancer cell biology. cancer genetics. infectious causes of cancer. tumor immunology. early detection and diagnosis. epidemiology. and cancer therapy. 2009 Impact Factor:4.